← All Vaccine Summaries Brought to you by the Open Source Medicine Foundation

Vaccine Evidence Summary

Rotavirus vaccine side effects: RotaTeq vs Rotarix, VAERS data, trials and schedule

This page answers “rotavirus vaccine side effects” with sourced pharmacovigilance data — intussusception signal with VAERS category view. Counts are database reports, not proven vaccine-caused injury rates.

Gold Standard EO (Aug 10, 2026) Federal recommendation status: Based on shared clinical decision-making

The August 10, 2026 Executive Order on Gold Standard Childhood Vaccine Recommendations places rotavirus in the Based on shared clinical decision-making category — not a universal recommendation for all children. The EO also expresses a preference, to the maximum extent feasible, for administering all childhood immunizations at separate medical visits.

Source: White House — Executive Order on Gold Standard Childhood Vaccine Recommendations (Aug 10, 2026) · Fact Sheet · EO 14407 (May 29, 2026) · Presidential Memorandum (Dec 5, 2025) · Federal Register, 91 FR 53173 (Aug. 14, 2026). These are federal recommendations; states set school-entry requirements. Always verify with current official sources.

Look up a vaccine lot or batch number in VAERS →

See the Rotavirus vaccine schedule in 26 countries →

Last updated: July 2026 · Status: Current U.S. licensed products reviewed

ⓘ Methodology Note

This page summarizes published data for rotavirus vaccines on the U.S. childhood schedule (RotaTeq®, RV5 and Rotarix®, RV1). Both are live attenuated oral vaccines. A prior rotavirus vaccine (RotaShield®, 1998) was withdrawn in 1999 due to an association with intussusception (~1 per 10,000 doses). This history is context for the extensive safety surveillance of current products. Data are presented without interpretive language that implies the vaccine is "safe" or "unsafe."

Evidence state

For each outcome: the specific question, what controlled studies found, and how certain that evidence is on the GRADE scale (high, moderate, low, very low). Ratings are editorial judgments by the site applying GRADE to the studies in the table below — observational evidence starts at low and is rated up for large, consistent effects or a dose/age gradient, and down for inconsistency or imprecision (Methods). Where an effect is confined to a subgroup (for example young males), the question says so. "Not searched" means no controlled study has been compiled here yet; it is not a finding that the outcome is rare or caused by the vaccine.

Outcome & questionFinding & certaintyWhy this rating
Intussusception
RotaTeq (RV5) and Rotarix (RV1), week after dose 1
increased risk (about 1–5 extra cases per 100,000 vaccinated infants, mostly in the week after the first dose)
High certainty
Start low; +2 very large effect after dose 1 (relative incidence ≈ 5) replicated in the US, Mexico and Brazil. Randomized trials were too small for an event this rare (pooled RR 1.14, 0.49–2.64): imprecise, not contradictory. Studies: Yih 2014, Weintraub 2014, Patel 2011, Shui 2012, Lu 2019. See table
AnaphylaxisNot searchedNo controlled-study result is compiled for this outcome yet.
Myocarditis or pericarditisNot searchedNo controlled-study result is compiled for this outcome yet.
Guillain-Barré syndromeNot searchedNo controlled-study result is compiled for this outcome yet.
Febrile seizureNot searchedNo controlled-study result is compiled for this outcome yet.
Immune thrombocytopeniaNot searchedNo controlled-study result is compiled for this outcome yet.

1. Basic Information

Disease Protected Against

Rotavirus is the leading cause of severe acute gastroenteritis in infants and young children globally. Before vaccination, rotavirus caused ~2.7 million cases of gastroenteritis, ~400,000 physician visits, ~70,000 hospitalizations, and ~20–60 deaths annually in U.S. children <5. Globally, rotavirus caused ~215,000 deaths/year in children <5 (pre-vaccine), predominantly in low-income countries. Transmission is fecal-oral. Almost all children are infected by age 3–5, regardless of sanitation quality.

CDC Schedule (U.S., 2025)

DoseRecommended AgeNotes
Dose 12 monthsMinimum age 6 weeks; maximum age for dose 1 = 14 weeks 6 days
Dose 24 monthsMinimum interval 4 weeks
Dose 3 (RotaTeq only)6 monthsRotaTeq (RV5) requires 3 doses; Rotarix (RV1) requires 2 doses. All doses must be completed by 8 months 0 days.

Source: CDC ACIP, 2025 schedule. The strict age window (must start by 14w6d, must finish by 8m0d) is due to a small background risk of intussusception in older infants unrelated to vaccination.

Licensed Rotavirus vaccine products

Each product has its own page with package-insert ingredients, side-effect data, lot lookup and comparisons with the other brands.

Ingredients (Package Insert)

Structured composition for 2 branded products covered on this page, taken from FDA-approved package inserts (DailyMed / manufacturer prescribing information). Lists are per product — formulations differ by manufacturer and presentation. Click an ingredient name to open its safety-context page when available.

Live attenuated Oral No preservative (typical single-dose) Polysorbate 80
RotaTeq Merck Sharp & Dohme LLC · Live attenuated

Delivery

Route: Oral

Form: Oral solution

Dose volume: 2 mL

Presentation: single-dose ready-to-use oral tube

Encapsulation / delivery vehicle

None (no nanoparticle/VLP encapsulation system)

Antigens

AntigenTypeAmount / dose
Live reassortant rotavirus G1Live attenuated virus≥2.2 × 10^6 infectious units
Live reassortant rotavirus G2Live attenuated virus≥2.8 × 10^6 infectious units
Live reassortant rotavirus G3Live attenuated virus≥2.2 × 10^6 infectious units
Live reassortant rotavirus G4Live attenuated virus≥2.0 × 10^6 infectious units
Live reassortant rotavirus P1A[8]Live attenuated virus≥2.3 × 10^6 infectious units

Adjuvants

None listed on the package insert for this product (common for live attenuated and some inactivated whole-virus vaccines).

Preservatives

  • None — Single-dose presentation; label states no preservative.

Excipients & residuals

IngredientCategoryAmountRole
SucroseStabilizerlabel quantitystabilizer/sweetener
Sodium citrate / phosphate buffersBufferlabel quantitybuffer
Polysorbate 80Surfactantlabel quantitysurfactant
Fetal bovine serumResidual (manufacturing)trace residualresidual

Source: FDA package insert · Verified 2026-07-09

Rotarix GlaxoSmithKline Biologicals · Live attenuated

Delivery

Route: Oral

Form: Oral solution

Dose volume: 1 mL

Presentation: oral applicator (liquid) or lyophilized + diluent (historical)

Encapsulation / delivery vehicle

None (no nanoparticle/VLP encapsulation system)

Antigens

AntigenTypeAmount / dose
Live attenuated human rotavirus RIX4414 (G1P[8])Live attenuated virus≥10^6.0 CCID50

Adjuvants

None listed on the package insert for this product (common for live attenuated and some inactivated whole-virus vaccines).

Preservatives

  • None — Single-dose presentation; label states no preservative.

Excipients & residuals

IngredientCategoryAmountRole
SucroseStabilizerlabel quantitystabilizer
Dulbecco's Modified Eagle Medium componentsResidual (culture)residual/mediamedia
Amino acids / saltsBufferlabel quantitybuffer

Source: FDA package insert · Verified 2026-07-09

ⓘ How to read this section

Ingredient lists are sourced from official package inserts for the specific brands named above. Formulations can change between lots and over time — verify against the current label before any clinical decision. Presence of a substance does not by itself indicate harm; toxicology is dose-, route-, and context-dependent. Browse the full ingredient database: Vaccine Ingredients index.

Causality assessment & potential mechanisms

Conditions below combine WHO-style causality levels with potential biological mechanisms from the site mechanism catalog (ae_mechanisms_catalog.json). HRSA VICP table listing (where shown) indicates a compensable temporal association under U.S. program rules — not automatic proof of causation for every case. Mechanisms are hypothesis-level pathways with graded evidence.

Condition Time window Causality Potential mechanism(s)
Intussusception HRSA table 1–21 days Very likely / Probable

Evidence: High

Intussusception after oral rotavirus vaccine (primary · innate_inflammation)

Oral rotavirus vaccines can promote lymphoid hyperplasia and altered gut motility that rare­ly lead to telescoping of intestine (intussusception), especially after dose 1.

Framework: WHO causality + HRSA VICP (where applicable) + AE mechanism catalog. Last updated: 2026-07-18. Schema: schemas/vaccine_injury_table.schema.json · Mechanisms: schemas/ae_mechanism.schema.json. Not medical or legal advice.

2. Pre-Licensure Clinical Trial Data

Licensure trial design (ICAN / OpenVAERS)

The table below reproduces ICAN’s No Placebo Table rows for U.S. childhood-schedule products relevant to this page — including the control/comparator used in FDA licensing trials (not always saline placebo). OSMF presents this for transparency; it is not an endorsement of ICAN interpretations.

Vaccine Brand Manufacturer Doses (schedule) Ages injected Control / comparator Placebo Safety review window
RV2RotarixGSK2 or 32M 4M 6MDextran, Sorbitol, Amino Acids, Dulbecco’s Modified Eagle Medium, and XanthanNo31 days + 1 year for intussusception
RV2RotaTeqMerck2 or 32M 4M 6MPolysorbate-80, Tissue Culture Medium, Fetal Bovine Serum, and Sodium PhosphateNo42 days + 1 year for intussusception

Source: OpenVAERS — No Placebo Table · ICAN original PDF · Attribution: Informed Consent Action Network (ICAN) via OpenVAERS · Last fetched: 2026-07-16. For many trials listing '6 months' safety review, ICAN notes review was typically ~30 days post-injection with a phone call at 6 months.

Current rotavirus vaccines were developed with intussusception safety specifically in mind, following the RotaShield experience. Both RotaTeq and Rotarix conducted very large pivotal trials.

MetricRotaTeq (RV5, Merck)Rotarix (RV1, GSK)
Pivotal trial size~70,000 infants (REST trial); ~35,000 received RotaTeq~63,000 infants; ~31,500 received Rotarix
Efficacy against severe rotavirus gastroenteritis~98% (U.S./Europe); lower in low-income settings (~50–65%)~85–96% (high-income); lower in low-income settings (~50–65%)
Efficacy against any rotavirus hospitalization~96%~85–96%
Intussusception (pre-licensure)No signal observed vs. placebo within 42 days (6 cases vs. 5 cases in placebo)No signal observed vs. placebo within 31 days

The REST (RotaTeq) and Rotarix pivotal trials are the largest pre-licensure vaccine trials ever conducted, with ~130,000+ infants combined. Both were specifically powered to evaluate intussusception risk.

Most Common Adverse Reactions

ReactionRotaTeq / Rotarix (Approx.)
Diarrhea~10–20% (mild, self-limited)
Vomiting~8–15%
Irritability~15–25%
Fever~10–20%

Adverse reactions are generally mild and self-limited (1–3 days). Rates are comparable to placebo in the large trials, reflecting the high background rate of these symptoms in infants.

Key Limitations

3. Post-Licensure Safety Data

Intussusception — Confirmed Post-Licensure Signal

Post-licensure VSD and international studies identified a small but statistically significant increased risk of intussusception following rotavirus vaccination, primarily in the 3–7 day window after the first dose.

The intussusception risk is acknowledged by ACIP, CDC, and WHO, and is included in product labeling. IOM (2012) concluded evidence favors acceptance of a causal relationship for rotavirus vaccine and intussusception.

Other Post-Licensure Findings

⚠ Critical Caveat

VAERS data represent unverified reports. A report to VAERS does not mean the vaccine caused the event.

VAERS reports per million doses

U.S. VAERS reports for vaccinations given 2006–2024, divided by the 167 million doses distributed in the same years (HRSA, from CDC data).

All reports
157
per million doses (155–159) · 26,214 reports
Serious reports
27.9
per million doses · 4,665 reports (death, life-threatening, hospitalised or disabled)
Reports with a death
4.08
per million doses · 682 reports

These are reporting rates: they mix real reactions, coincidental events and reports of conditions that would have happened anyway, and they depend on how actively each vaccine is watched. Doses are distributed, not administered. Combination vaccines count toward each component in both numerator and denominator. Compare with the observed-vs-expected analysis and the controlled studies above. Data: vaers_reporting_rates.json.

All vaccines, per million doses
VaccineAllSeriousDeath
pcv26628.13.23
rotavirus15727.94.08
hpv33525.32.00
hib12619.73.25
polio15217.62.77
mmr32015.30.94
varicella37214.10.84
hepatitis-b11012.72.15
meningococcal21411.80.70
dtap13211.21.31
hepatitis-a1528.50.58
influenza685.40.48

What controlled safety studies found

Unlike VAERS counts, these studies compare vaccinated people with a control group or control time window, so they can estimate whether a risk is raised and by how much. 8 results for rotavirus vaccines: 4 found an increased risk of a specific outcome, 3 found no increased risk.

OutcomeDesign & populationEstimate (95% CI)Excess per million dosesFindingSource
Intussusception
Rotarix (RV1)
cohort, sequential vs historical and vs concurrent RV5 recipients (VSD)
Infants 4-34 wk, US (207,955 RV1 doses)
RR (vs RV5) 9.4 (1.4–103.8)—increased riskWeintraub ES et al., 2014, N Engl J Med
doi:10.1056/NEJMoa1311738; PMID 24422678
Intussusception (dose 1)
RotaTeq (RV5)
self-controlled risk interval (FDA Mini-Sentinel)
Infants 5-37 wk, US (507,874 first doses)
attributable risk per 100,000 first-dose recipients 1.5 (0.2–3.2)—increased riskYih WK et al., 2014, N Engl J Med
doi:10.1056/NEJMoa1303164; PMID 24422676
Intussusception (dose 1)
Rotarix (RV1)
SCCS (active hospital surveillance)
Infants, Mexico
IRR (relative incidence) 5.3 (3.0–9.3)—increased riskPatel MM et al., 2011, N Engl J Med
doi:10.1056/NEJMoa1012952; PMID 21675888
Intussusception (dose 2)
Rotarix (RV1)
SCCS + case-control (active hospital surveillance)
Infants, Brazil
——increased riskPatel MM et al., 2011, N Engl J Med
doi:10.1056/NEJMoa1012952; PMID 21675888
Intussusception
Rotarix (RV1)
self-controlled risk interval + cohort (FDA Mini-Sentinel)
Infants, US (53,638 first doses)
——inconclusiveYih WK et al., 2014, N Engl J Med
doi:10.1056/NEJMoa1303164; PMID 24422676
Intussusception
RV1, RV5 and others (RCTs)
meta-analysis of RCTs
Infants, 33 countries (25 trials, 200,594 participants)
RR 1.14 (0.49–2.64)—no increased risk detectedLu HL et al., 2019, JAMA Netw Open
doi:10.1001/jamanetworkopen.2019.12458; PMID 31584679
Intussusception (all doses)
RotaTeq (RV5)
cohort vs historical background (VSD)
Infants 4-34 wk, US (786,725 doses)
SIR 1.01 (0.62–1.54)—no increased risk detectedShui IM et al., 2012, JAMA
doi:10.1001/jama.2012.97; PMID 22318281
Kawasaki disease
RotaTeq/Rotarix
self-controlled risk interval (VSD)
Children <2 y, US, born 2006-2017
RR (age-adjusted) 0.66 (0.4–1.09)—no increased risk detectedKamidani S et al., 2022, Pediatrics
doi:10.1542/peds.2022-058789; PMID 36349537

Compiled from study abstracts and FDA/CDC pages, verified 2026-10-09; full table with every source on vaccine safety studies. Data: active_surveillance_results.json, disease_risks.json.

Trials, timing and other data sources

Randomized placebo-controlled trials: serious adverse events

Trials on ClinicalTrials.gov with posted results and a placebo, saline or no-vaccine control arm (55,641 vaccinated vs 48,615 controls), pooled with a random-effects model:

Rotavirus gastroenteritis that leads to hospitalisation is itself recorded as a serious adverse event, so a vaccine that prevents it shows fewer serious events than placebo.

Trials included
TrialTitleVaccine: SAE/nControl: SAE/n
NCT00090233Rotavirus Efficacy and Safety Trial (REST)(V260-006)863/34,904955/34,862
NCT00362648Developing World Study for RotaTeq™ (V260-015)(COMPLETED)145/3,748156/3,745
NCT00092443Dose Confirmation Efficacy Study (V260-007)21/64928/658
NCT00092456Consistency Lots Vaccine Study (V260-009)10/6793/111
NCT00718237Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-027/3809/381
NCT00880698Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children 7/998/103
NCT00329745Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or10/4,35911/4,328
NCT01171963Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine,183/1,666246/1,667
NCT00241644Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinat842/6,596246/1,641
NCT00420316Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses4/1,0827/531
NCT00480324Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infan72/50844/257
NCT00969228Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean 17/50813/176
NCT01616693Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines10/4634/155

Only blinded, placebo-controlled periods are used (open-label, crossover, booster and extension periods excluded) and vaccine and placebo arms are matched within the same trial part. Risk ratios use participant counts, not person-time: where placebo recipients crossed over to vaccine, the placebo arm is followed for less time, which pushes count-based ratios up. Serious adverse events are sponsor-coded and include events unrelated to vaccination; trials were powered for efficacy, not rare harms; most childhood-vaccine trials use active comparators and therefore do not appear here. Code: analysis/vaccine_trial_meta.py; data: vaccine_trial_meta.json.

When do reported events start? (time to onset)

Days from vaccination to onset in U.S. VAERS reports (0–180 days). A causal reaction usually starts inside a characteristic window; but people also report what happens soon after a shot, so each event is compared with all other reports for this vaccine. The Weibull shape measures bunching (below 1 = most onsets early).

EventReportsMedian daysIn risk windowShape (95% CI) vs othersReading
Intussusception1,286863% (others 29%)0.82 (0.80–0.85) vs 0.66spread later than other reports
Seizure (any)781196% (others 97%)0.69 (0.64–0.74) vs 0.66same timing as other reports
Febrile seizure152197% (others 97%)0.69 (0.61–0.89) vs 0.66same timing as other reports
Sudden infant death104373% (others 95%)0.93 (0.86–1.04) vs 0.66spread later than other reports
Kawasaki disease691074% (others 30%)0.77 (0.67–0.93) vs 0.66same timing as other reports
Syncope41073% (others 83%)0.53 (0.45–0.76) vs 0.66same timing as other reports
ADEM / encephalitis21038% (others 30%)0.52 (0.44–0.69) vs 0.66same timing as other reports

Timing alone cannot establish causation; it can make it more or less plausible. *Fitted on a random sample of 5,000 of these reports. Data: vaers_onset.json.

VAERS Reporting Data — Halma & Varon (2025), DARE-SAFE

The DARE-SAFE paper (Halma & Varon, Pharmacoepidemiology 2025, CC BY 4.0) analyzed VAERS reports for vaccines administered in the United States from 2006–2022. The following data are extracted from Table 1 of that paper for this vaccine (Rotavirus (RotaTeq + Rotarix combined)):

MetricValue
U.S. doses administered (2006–2022)150,866,652
Total VAERS AE reports19,899
AE reporting rate (per 100,000 doses)13.2
Total death reports476
Death reporting rate (per 100,000 doses)0.316
AE-to-Death ratio42:1

Source: Halma, M.; Varon, J. DARE-SAFE. Pharmacoepidemiology. 2025. DOI: 10.3390/pharma4020007. CC BY 4.0. Data from Table 1.

📚 Important Interpretive Caveats (from the paper itself)

  • Reporting rate ≠ incidence rate. VAERS is a passive, unverified system. A report means someone submitted a claim of temporal association, not a confirmed causal event. The paper is explicit that causality cannot be inferred from these numbers alone.
  • Reporting behavior is not uniform. More serious, unusual, or media-salient events are reported at much higher rates than mild ones. Products receiving more public, media, legal, and clinical attention (particularly COVID-19 vaccines, which also benefited from V-safe active-surveillance prompts and CICP compensation pathways) generate more reports per dose regardless of true risk.
  • Age and comorbidity confounding is not adjusted. COVID-19 vaccines were disproportionately administered to elderly and comorbid populations (nursing homes, 65+, high-risk groups in early 2021) with much higher background all-cause mortality than the general child/working-age population. Some fraction of temporally-associated deaths would occur regardless of vaccination, and the paper does not perform a background-rate comparison.
  • Stimulated reporting is a known, documented phenomenon. Media coverage, plaintiff attorney solicitation, and advocacy campaigns — all independently inflate VAERS reporting propensity. The paper cites this literature but does not correct for it.
  • Small-denominator rows are unreliable. Rates computed from small denominators (e.g., monovalent measles, DT, mumps, rubella) have enormous statistical uncertainty and should not be compared to vaccines with hundreds of millions of administered doses without noting the wide confidence intervals.

Source: Halma, M.; Varon, J. DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines. Pharmacoepidemiology. 2025, 4, 7. DOI: 10.3390/pharma4020007. CC BY 4.0.

Passive Surveillance: AE Type Breakdown (Multi-System)

Side-by-side view of U.S. VAERS, Health Canada Canada Vigilance, Japan JADER (PMDA), EU EudraVigilance, and live-scraped international systems via SurVigilance (VigiAccess, Lareb, DAEN, DMA, Medsafe). SurVigilance panels show MedDRA PT mention totals (not individual-case counts). Category assignment uses keyword matching — approximate, not official SOC coding. VAERS files on this site are built from the public VAERS download. FAERS figures use the public quarterly FAERS files. Counts are mentions or reports, not incidence.

VAERS (United States)

Canada Vigilance (Canada)

JADER (PMDA, Japan)

EudraVigilance (EU)

No matching vaccine cases in the current EudraVigilance DAP export.

SurVigilance: VigiAccess · Lareb · DAEN · DMA · Medsafe

VigiAccess (WHO)

Lareb (Netherlands)

DAEN (Australia)

This system’s totals are not in this panel. Published counts, when this site has them, are in the surveillance section.

DMA (Denmark)

Denmark DMA interactive ADR search is currently offline (Danish Medicines Agency IT transition; public overviews frozen at 12 Mar 2024). Live product PT tables cannot be retrieved until DKMA restores the search. See DKMA notice. Denmark continues to report into EU EudraVigilance (panel above).

Medsafe (New Zealand)

VAERS (U.S., 2006–2024): 25,405 symptom mentions (5.61/100k doses). Largest share: Other / Unclassified (74%), Gastrointestinal (11%), General / Systemic (non-local) (4%). Canada Vigilance (CV Online extract): 187 reaction mentions in 65 unique reports (84.6% serious (55 of 65 reports)). Largest share: Gastrointestinal (28%), Thrombotic / Hematological (9%), General / Systemic (non-local) (8%). JADER (PMDA public CSV extract): 2,763 reaction mentions in 1,217 unique reports (0.7% serious (8 of 1,217 reports)). Largest share: Gastrointestinal (46%), Other / Unclassified (37%), General / Systemic (non-local) (7%). VigiAccess (WHO): 250,075 reaction-term mentions · search: rotavirus. Largest share: Other / Unclassified (26%), Gastrointestinal (20%), General / Systemic (non-local) (15%). Lareb (Netherlands): 3,974 reaction-term mentions · search: Rotavirus vaccine. Largest share: Gastrointestinal (34%), General / Systemic (non-local) (26%), Other / Unclassified (18%). Medsafe (New Zealand): 1,120 reaction-term mentions · search: rotavirus. Largest share: Gastrointestinal (47%), Other / Unclassified (14%), General / Systemic (non-local) (13%). Cross-database note: All systems are passive and unverified; reporting rates are not directly comparable across countries (different populations, reporting incentives, and lack of dose denominators for Canada/Japan/EU). top VAERS: Other / Unclassified; top Canada Vigilance: Gastrointestinal; top JADER: Gastrointestinal. SurVigilance note: VigiAccess, Lareb, DAEN, DMA, and Medsafe counts are live-scraped MedDRA PT mention totals (not deduplicated individual cases). Data via SurVigilance (GPL-3.0; pip install SurVigilance). Category assignment uses keyword matching on reported reaction terms — approximate and exploratory. Neither database establishes causality.

Compare AE patterns across all vaccines →

Pharmacovigilance Lot Signal Detection — Hypothesis-Generating Only

Multi-system context below. VAERS (U.S.) supports lot-level volume z-scores and seriousness flags by product and lot (2006–2026). Each lot links to a summary with report count, seriousness %, adverse-event pie chart, U.S. state map, and timeline. A signal flag means a statistical threshold was exceeded — not that a lot is unsafe. Full dashboard →

VAERS flags: VOL high report volume (z ≥ 3) · BURST clustered in <90 days · SER serious reports >50%. Lot numbers are voluntary/incomplete in VAERS. Location data is U.S. state only (no postal codes in the public extract).

VAERS (United States) — all lots by product

5,886 reports with usable lot across 732 lots · 117 flagged

Loading lot tables…

Other Pharmacovigilance Systems

Lot-level analysis is only possible where reporters supply batch/lot numbers in the public extract. Canada Vigilance, JADER (PMDA, Japan), and most other national systems publish product-level spontaneous reports without lot fields.

Canada Vigilance (Health Canada)

65 unique reports · 187 reaction mentions · 84.6% serious (55 of 65 reports). Top categories: Gastrointestinal (28%), Thrombotic / Hematological (9%), General / Systemic (non-local) (8%).

Canada Vigilance spontaneous reports are unverified temporal associations. The public CV Online data extract does not include lot or batch numbers, so lot-level signal detection is not possible for this system — only product-level reaction patterns are shown here. No Canadian dose denominators are available. Extract 2026-03-31.

Search Canada Vigilance →

JADER (PMDA, Japan)

1,217 unique reports · 2,763 reaction mentions · 0.7% serious (8 of 1,217 reports). Top categories: Gastrointestinal (46%), Other / Unclassified (37%), General / Systemic (non-local) (7%).

JADER (Japanese Adverse Drug Event Report database) spontaneous reports are unverified temporal associations; PMDA has not assessed causality per case. The public CSV extract does not include lot or batch numbers, so lot-level signal detection is not possible — only product-level reaction patterns are shown here. Reaction terms in source data use MedDRA/J Preferred Terms. JADER CSV extract pmdacasereport202606 (2026-06). JADER reference (PDF)

Search JADER / PMDA adverse reactions →

No EudraVigilance (EU) summary is mapped for this page.

VigiAccess (WHO)

250,075 MedDRA PT mentions · search: rotavirus. Top categories: Other / Unclassified (26%), Gastrointestinal (20%), General / Systemic (non-local) (15%).

Live-scraped public portal data via SurVigilance (GPL-3.0). Counts are reaction-term mentions, not deduplicated individual cases. No lot/batch field.

Search VigiAccess (WHO) →

Lareb (Netherlands)

3,974 MedDRA PT mentions · search: Rotavirus vaccine. Top categories: Gastrointestinal (34%), General / Systemic (non-local) (26%), Other / Unclassified (18%).

Live-scraped public portal data via SurVigilance (GPL-3.0). Counts are reaction-term mentions, not deduplicated individual cases. No lot/batch field.

Search Lareb (Netherlands) →

SystemRegionLot data
VAERSUnited StatesLot data
Canada VigilanceCanadaNo public lot field
JADER (PMDA, Japan)JapanNo public lot field
Lareb (Netherlands)NetherlandsNo public lot field
EudraVigilanceEuropean UnionNo public lot field
VigiAccess (WHO)GlobalNo public lot field
Yellow Card (UK)United KingdomNo public lot field
DAEN (Australia)AustraliaNo public lot field

All global data sources → · Data schemas →

Active Pharmacovigilance (Defined-Population Surveillance)

Curated findings for Rotavirus vaccines (RotaTeq / Rotarix) from active systems (not VAERS). Page inventory last reviewed: 2026-07-10.

ⓘ Active vs. passive — why this pane is separate

The VAERS / multi-system charts above are passive surveillance: spontaneous, unverified reports without a fixed denominator. Active surveillance starts from a defined, enumerated population (EHR/claims or structured post-vaccination surveys), applies pre-specified statistical tests, and asks whether an outcome occurs more often than expected in a risk window versus a comparison window or group. These are not two flavors of the same evidence — active findings are the harder tier that can confirm, refute, or leave under investigation a signal first hinted in passive data. Do not add VAERS report counts to active incidence rates.

○ No signal detected ◐ Signal under investigation ◑ Investigated — not confirmed ● Signal confirmed (true association) – Not currently under active surveillance

CDC Vaccine Safety Datalink (VSD)

Outcome: Intussusception

Tier 2 ● Signal confirmed (true association)

Active surveillance confirmed a small increased risk of intussusception after current rotavirus vaccines (on the order of ~1–5 excess cases per 100,000 vaccinated infants in published estimates, product- and window-dependent). Risk is much lower than with the withdrawn RotaShield product; benefits against severe gastroenteritis remain the policy rationale for continued use.

Population

Infants receiving monovalent and pentavalent rotavirus vaccines

Risk interval

Typically 1–7 and 1–21 days after dose 1 (and additional dose windows in some analyses)

Comparison

Control intervals / unexposed person-time

Evaluation period

Post-licensure U.S. monitoring (key NEJM report 2014 for monovalent product)

Method

Active surveillance / cohort and self-controlled designs with chart validation

Related passive AE category on this page: Gastrointestinal (see multi-system charts above — not additive with active rates).

Sources: Weintraub ES et al. NEJM 2014 — intussusception after monovalent rotavirus vaccine · CDC VSD

Record last reviewed: 2026-07-10

Update cadence: Tier 1: check AusVaxSafety monthly when public pages update. Tier 2/3: quarterly review around ACIP meetings and PubMed/MMWR; set lastReviewed per record. Source tiers: Tier 1 = public near-real-time dashboards (e.g. AusVaxSafety); Tier 2 = VSD / Sentinel / PRAC-type findings released via ACIP slides, MMWR, or papers (no public VSD raw dashboard); Tier 3 = regulator label/safety communications. Detecting a signal and later classifying it as not confirmed is normal system behavior — not an anomaly to hide or amplify.

4. Documented Adverse Events

Rank-aggregated VAERS signal detection (rankv)

The table below lists vaccine–event pairs that were detected as disproportionality signals by all four base methods used in rankv (GPS, PRR, ROR, BCPNN) on multi-decade VAERS data, then ordered by rank aggregation (Borda average rank; related to the Spearman/GA top-list approach in the rankv paper).

Agg. rank VAERS product Preferred term (event) N Method ranks (GPS / PRR / ROR / BCPNN)
2 ROTAVIRUS (ROTASHIELD) Gastrointestinal haemorrhage
clinical-coded PT · published top-25
94 GPS rank 2 (EBGM=112.59); PRR rank 8 (PRR=343.7149); ROR rank 8 (ROR=361.035); BCPNN rank 6 (IC_LB=5.8346)
31 ROTAVIRUS (ROTASHIELD) Intestinal obstruction
clinical-coded PT
23 GPS rank 14 (EBGM=46.73); PRR rank 40 (PRR=150.3139); ROR rank 40 (ROR=152.0924); BCPNN rank 99 (IC_LB=3.7254)
77 ROTAVIRUS (ROTASHIELD) Gastroenteritis
clinical-coded PT
30 GPS rank 78 (EBGM=22.47); PRR rank 95 (PRR=58.4477); ROR rank 93 (ROR=59.3435); BCPNN rank 89 (IC_LB=3.7933)
91 ROTAVIRUS (ROTATEQ) Rotavirus test positive
clinical-coded PT
246 GPS rank 175 (EBGM=7.59); PRR rank 100 (PRR=45.2311); ROR rank 100 (ROR=45.5059); BCPNN rank 36 (IC_LB=4.5275)
95 ROTAVIRUS (ROTASHIELD) Constipation
clinical-coded PT
37 GPS rank 105 (EBGM=18.0); PRR rank 125 (PRR=40.0525); ROR rank 122 (ROR=40.8062); BCPNN rank 87 (IC_LB=3.7983)
97 ROTAVIRUS (ROTATEQ) Rotavirus infection
clinical-coded PT
129 GPS rank 233 (EBGM=6.72); PRR rank 86 (PRR=57.0732); ROR rank 86 (ROR=57.2553); BCPNN rank 40 (IC_LB=4.4775)
102 ROTAVIRUS (ROTATEQ) Oral administration complication
clinical-coded PT
70 GPS rank 255 (EBGM=6.74); PRR rank 79 (PRR=67.5708); ROR rank 79 (ROR=67.688); BCPNN rank 53 (IC_LB=4.2281)
113 ROTAVIRUS (ROTATEQ) Haematochezia
clinical-coded PT
769 GPS rank 160 (EBGM=7.53); PRR rank 144 (PRR=23.4892); ROR rank 142 (ROR=23.9319); BCPNN rank 61 (IC_LB=4.0715)
114 ROTAVIRUS (ROTASHIELD) Melaena
clinical-coded PT
12 GPS rank 117 (EBGM=28.21); PRR rank 66 (PRR=108.9005); ROR rank 66 (ROR=109.5673); BCPNN rank 259 (IC_LB=2.6617)
118 ROTAVIRUS (ROTATEQ) Intussusception
clinical-coded PT
867 GPS rank 153 (EBGM=7.87); PRR rank 154 (PRR=22.2368); ROR rank 152 (ROR=22.7092); BCPNN rank 66 (IC_LB=4.0212)
128 ROTAVIRUS (ROTATEQ) Gastroenteritis rotavirus
clinical-coded PT
73 GPS rank 308 (EBGM=6.09); PRR rank 89 (PRR=58.5007); ROR rank 90 (ROR=58.6062); BCPNN rank 55 (IC_LB=4.1822)
131 ROTAVIRUS (ROTATEQ) Mucous stools
clinical-coded PT
194 GPS rank 185 (EBGM=7.3); PRR rank 150 (PRR=24.9312); ROR rank 149 (ROR=25.0483); BCPNN rank 72 (IC_LB=3.9253)
133 ROTAVIRUS (ROTATEQ) Enema administration
clinical-coded PT
248 GPS rank 173 (EBGM=7.61); PRR rank 160 (PRR=22.5071); ROR rank 160 (ROR=22.6418); BCPNN rank 76 (IC_LB=3.8736)
134 ROTAVIRUS (ROTATEQ) Occult blood positive
clinical-coded PT
171 GPS rank 180 (EBGM=7.52); PRR rank 155 (PRR=24.0493); ROR rank 156 (ROR=24.1487); BCPNN rank 79 (IC_LB=3.8579)
140 ROTAVIRUS (ROTASHIELD) Abnormal faeces
clinical-coded PT
20 GPS rank 200 (EBGM=14.81); PRR rank 104 (PRR=57.52); ROR rank 104 (ROR=58.1045); BCPNN rank 171 (IC_LB=3.2782)

Showing up to 15 pairs for this page (clinical-coded terms listed first). Full processed tables: rankv_signals.json.

  • Methods combined: BCPNN (IC), GPS/EBGM, PRR, ROR — then rank aggregation.
  • Data: ~30 years of public VAERS (rankv processed tables).
  • Origin: precisionFDA “Gaining New Insights by Detecting Adverse Event Anomalies” challenge solution.
  • Caveat: Disproportionality signals are statistical associations in spontaneous reports. They do not establish causality, incidence, or product defect. Many top pairs reflect administration/product-use coding rather than clinical injury.

Source: nanx.me/rankv · Code: github.com/nanxstats/rankv (MIT) · Built: 2026-07-30.

▶ Strong Evidence of Causal Association

▶ No Causal Association

5. Disease Prevention Benefits

MetricPre-Vaccine EraPost-Vaccine Era (U.S.)
Rotavirus hospitalizations (annual, children <5)~55,000–70,000>90% reduction; ~4,000–6,000 hospitalizations/year
Rotavirus ER visits (annual, <5)~200,000~80–85% reduction
Rotavirus deaths (annual, U.S., <5)~20–60<5/year
Global rotavirus deaths (2000 vs. 2022)~528,000 (2000)~128,000 (2022) — ~76% reduction

Source: CDC Pink Book; WHO. Substantial herd protection has been observed, with declines in rotavirus disease in unvaccinated older children and adults.

Disease Burden Over Time

Reported U.S. disease burden by year. The dashed vertical line marks vaccine introduction. Hover or tap data points for values; use arrow keys when a chart has focus.

ⓘ About these charts: These are accessible SVG line charts with keyboard navigation, hover tooltips, and an underlying data table (expand below). The dashed vertical line marks the year of vaccine introduction. Reported cases undercount true incidence; case definitions, reporting practices, and diagnostic methods have changed over time. See Section 5 for additional context and pre-vs-post era comparisons.

7. Evidence Summary

Rotavirus vaccines have been studied in the largest pre-licensure trials in vaccine history (N=130,000+ combined), specifically designed to evaluate intussusception risk. The post-licensure identification of a small intussusception risk (~1–5 per 100,000 first doses) is an example of the surveillance system functioning as designed—detecting a risk too small to be identified even in the very large pre-licensure trials. The benefit-risk ratio strongly favors vaccination. The primary evidence gap is the lower efficacy in low-income countries, an active area of research.

DomainEvidence Grade
Efficacy (severe rotavirus disease, high-income)Strong
Intussusception riskStrong
Efficacy (low-income settings)Moderate

8. International Surveillance & Global Data

Quick links to public pharmacovigilance databases and trial registries relevant to Rotavirus Vaccine. Reporting counts do not establish causality.

9. Curated Adverse Event Literature

Curated peer-reviewed literature linking specific adverse events to Rotavirus Vaccine. Each entry is a case report, case series, or related safety publication identified via PubMed. Expand Search PubMed for additional literature below to run custom queries.

Common questions

How long do Rotavirus vaccine side effects last?

Most reported Rotavirus vaccine reactions are short-lived: injection-site soreness, tiredness, and low-grade fever that typically begin within a day or two and resolve within a few days. Longer-lasting or more serious events are rarer and are the ones tracked in the post-licensure surveillance and documented adverse-event sections of this page, with report counts that are not incidence rates. Anything severe or persisting beyond a week warrants medical review.

Is the Rotavirus vaccine given to adults, and are side effects different in adults?

Whether the Rotavirus vaccine is recommended for adults depends on the vaccine and the person's risk factors; the schedule and product sections above describe the licensed indications and age groups. Reporting patterns in adults can differ from children, so this page's VAERS and international database breakdowns should be read with the reporting population in mind. Check the current CDC/ACIP adult schedule and the product's prescribing information for adult dosing.

10. Key References

  1. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23–33. (REST trial; N=68,038)
  2. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11–22. (Rotarix pivotal trial; N=63,225)
  3. IOM. Adverse Effects of Vaccines: Evidence and Causality. National Academies Press; 2012.
  4. Weintraub ES, et al. Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med. 2014;370(6):513–519.
  5. Yih WK, et al. Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med. 2014;370(6):503–512. (VSD study)
  6. CDC. Pink Book — Rotavirus chapter. cdc.gov/pinkbook
  7. CDC. VSD. cdc.gov/vaccine-safety/about/vsd.html
  8. CDC/FDA. VAERS. vaers.hhs.gov
🧪

Next-Gen Pipeline & Clinical Candidates

Active investigational vaccine candidates and next-generation platforms in clinical development

View Full Pipeline Hub →
Phase 3 Primary completion (most advanced trial): 2025-01-04 (registry estimate)

ROTAVAC 5D

Bharat Biotech International Limited

Biological (unspecified platform) Dossier →
Discontinued Primary completion (most advanced trial): 2010-08 (registry estimate)

Rotavirus Vaccine, Live, Oral, Pentavalent

Merck Sharp & Dohme LLC

Biological (unspecified platform) Dossier →
Phase 2 Primary completion (most advanced trial): 2026-06-15 (registry estimate)

Oral hexavalent reassortant rotavirus attenuated live vaccine

Sinovac Life Sciences Co., Ltd.

Biological (unspecified platform) Dossier →

7. Compensation

Not searched. No primary source linked for this section on this page.

8. Risk-benefit and gaps

Not searched. No primary source linked for this section on this page.

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation

Home of the OSMF network — open-source pharmacovigilance tools and evidence-based medicine resources.

Research Tracker

Track peer-reviewed literature on vaccine safety, pharmacovigilance, and post-market surveillance.

Evidence Desk

Soft launch — provisional claim grades; not medical advice. Does not contain vaccine lot or VAERS data.

SpikeProtein.site

Comprehensive resource on spike protein biology, biodistribution, and clinical implications.

VitalScan4PACVS

Decentralized trial for PACVS (post-acute COVID-19 vaccination syndrome).

PACVS Research Summit

Weekly seminar series for researchers and clinicians studying post-acute COVID-19 vaccination syndrome.